Insider Selling: Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Sells 689 Shares of Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 689 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $12,581.14. Following the completion of the transaction, the chief operating officer now directly owns 336,136 shares of the company’s stock, valued at approximately $6,137,843.36. This trade represents a 0.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Fulgent Genetics Stock Up 1.3 %

Shares of NASDAQ:FLGT opened at $18.30 on Friday. The firm has a market cap of $559.80 million, a P/E ratio of -3.32 and a beta of 1.51. Fulgent Genetics, Inc. has a 12-month low of $16.56 and a 12-month high of $30.68. The business has a fifty day simple moving average of $19.79 and a 200 day simple moving average of $21.11.

Hedge Funds Weigh In On Fulgent Genetics

Several hedge funds and other institutional investors have recently bought and sold shares of FLGT. Asset Dedication LLC acquired a new stake in Fulgent Genetics during the second quarter worth approximately $33,000. nVerses Capital LLC bought a new position in shares of Fulgent Genetics during the 2nd quarter worth approximately $43,000. Signaturefd LLC boosted its holdings in shares of Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after buying an additional 1,132 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Fulgent Genetics during the 3rd quarter worth approximately $46,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Fulgent Genetics in the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Analysts Set New Price Targets

FLGT has been the subject of a number of research reports. StockNews.com cut shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday. Piper Sandler dropped their price objective on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Monday, November 11th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.